Stoke Therapeutics, Inc.

NASDAQ:STOK

Biotechnology

Healthcare
$26.93 -1.12%

-$0.34 today

Market cap
$1.76B
Beta
1.19
P/E (TTM)
-11.1
EPS (TTM)
-$2.69
52W Low $11.17High $40.22

Volume 0.64M

Average 0.64M

Income Statement

Follow revenue through to earnings.

Revenue

$184.42M

FY 2025 · Annual

+404.5% YoY

Operating Income

-$20.59M

FY 2025 · Annual

Net Income

-$6.88M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue012.41M8.78M36.56M184.42M
Cost of Revenue00000
Gross Profit012.41M8.78M36.56M184.42M
Gross Margin—100.0%100.0%100.0%100.0%
Research & Development54.17M77.84M82.23M89.13M137.92M
Selling, General & Admin31.9M38.92M41.32M48.79M67.09M
Operating Expenses86.07M116.76M123.55M137.93M205.01M
Depreciation & Amortization974K1.55M2.47M2.18M1.77M
EBITDA(84.83M)(99.52M)(102.23M)(86.8M)(5.12M)
EBITDA Margin—-802.3%-1164.4%-237.5%-2.8%
Operating Income(86.07M)(104.36M)(114.77M)(101.37M)(20.59M)
Operating Margin—-841.2%-1307.2%-277.3%-11.2%
Interest Income120K3.12M9.91M12.64M13.77M
Interest Expense00009K
Other Income / Expenses260K3.29M10.07M12.39M13.71M
Income Before Tax(85.81M)(101.07M)(104.7M)(88.98M)(6.89M)
Pre-Tax Margin—-814.7%-1192.5%-243.4%-3.7%
Income Tax Expense00000
Net Income(85.81M)(101.07M)(104.7M)(88.98M)(6.89M)
Net Margin—-814.7%-1192.5%-243.4%-3.7%
EPS (Basic)(2.34)(2.60)(2.38)(1.65)(0.12)
EPS (Diluted)(2.34)(2.60)(2.38)(1.65)(0.12)
Weighted Avg Shares36.74M38.9M43.99M54.01M59.22M
Weighted Avg Shares (Diluted)36.74M38.9M43.99M54.01M59.22M

STOK Earnings Waterfall · TTM

NASDAQ:STOK · Revenue to Net Income

Key Ratios

EPS$-2.83
Gross Margin74.7%
Net Margin-1366.4%
P/E Ratio-8.6
P/S Ratio457.3

Analysis

$32.1M of revenue converted into -$169.8M of net income for the selected period. Gross margin is 74.7% and net margin is -1366.4%, showing how much revenue survives after costs and taxes. EPS is $-2.83, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
SC 13G/ASC 13G/A filingNov 5, 2026
4Statement of changes in beneficial ownershipNov 4, 2026
10-QQuarterly reportNov 3, 2026
8-KCurrent reportOct 29, 2026

How much revenue does STOK generate?

Stoke Therapeutics, Inc. (STOK) reported $184.42M of revenue in fiscal 2025.

Is STOK profitable?

Stoke Therapeutics, Inc. (STOK) reported -$6.88M of net income, with a net margin of -3.7%.